Prioritizing HIV comparative effectiveness trials based on value of information: Generic versus brand-name ART in the US

HIV Clinical Trials

Volumn 16, Issue 6, 2015, Pages 207-218

  Pei, Pamela P ^a   Weinstein, Milton C ^b,c   Li, X Cynthia ^a   Hughes, Michael D ^b   Paltiel, A David ^d   Hou, Taige ^a   Parker, Robert A ^a,c   Gaynes, Melanie R ^a   Sax, Paul E ^c,e   Freedberg, Kenneth A ^a,b,c   Schackman, Bruce R ^f   Walensky, Rochelle P ^a,c,e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d YALE UNIVERSITY   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Cost effectiveness analysis; Decision modeling; Generic drugs; HIV; Value of information

Indexed keywords

ANTIRETROVIRUS AGENT; GENERIC DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; COMPARATIVE EFFECTIVENESS; CONSUMER HEALTH INFORMATION; COST EFFECTIVENESS ANALYSIS; DRUG COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; QUALITY OF LIFE; SENSITIVITY ANALYSIS; UNITED STATES; CLINICAL TRIAL (TOPIC); COST BENEFIT ANALYSIS; ECONOMIC MODEL; ECONOMICS; HIV INFECTIONS;

ANTI-HIV AGENTS; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUGS, GENERIC; HIV INFECTIONS; HUMANS; MODELS, ECONOMIC; UNITED STATES;

EID: 84971574756     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1179/1945577115Y.0000000009     Document Type: Article

References (54)

1. B.Groot Koerkamp, M.G.Myriam Hunink, T.Stijnen, M.C.Weinstein. Identifying key parameters in cost-effectiveness analysis using value of information: a comparison of methods. Health Econ. 2006;15(4):383–392.
2. B.Groot Koerkamp, M.C.Weinstein, T.Stijnen, M.H.Heijenbrok-Kal, M.G.Hunink. Uncertainty and patient heterogeneity in medical decision models. Med Decis Making. 2010;30(2):194–205.
3. A.S.Fauci, M.I.Johnston, C.W.Dieffenbach, D.R.Burton, S.M.Hammer, J.A.Hoxie, HIV vaccine research: the way forward. Science. 2008;321(5888):530–532.
4. K.P.High, M.Brennan-Ing, D.B.Clifford, M.H.Cohen, J.Currier, S.G.Deeks, HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr. 2012;60:S1–S18.
5. Institute of Medicine (US) Forum on Drug Discovery, Development, and Translation. Challenges in Clinical Research. Transforming clinical research in the United States: challenges and opportunities: workshop summary. Washington, DC: Available from: http://www.ncbi.nlm.nih.gov/books/NBK50888/. Accessed July 24, 2015National Academics Press (US); 2015.
6. C.Jervis. HIV/AIDS clinical trials network to take on new research priorities under severe funding constraints. 2011;. Available from: http://www.treatmentactiongroup.org/tagline/2011/winter/clinical-trials-network-new-priorities. Accessed July 24, 2015.
7. G.Lopes. NIH cuts ACTG AIDS research funding. 2006;. Available from: http://www.natap.org/2007/newsUpdates/010207_17.htm. Accessed July 24, 2015.
8. P.E.Sax. Generic lamivudine has arrived. 2015;. NEJM Journal Watch Blogs; Available from: http://blogs.jwatch.org/hiv-id-observations/index.php/generic-lamivudine-has-arrived/2012/01/22/. Accessed July 24, 2015.
9. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. 2015;. Available from: https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed June 6, 2015.
10. D.M.Cutler, A.B.Rosen, S.Vijan. The value of medical spending in the United States, 1960-2000. N Engl J Med. 2006;355(9):920–927.
11. C.Gopalappa, P.G.Farnham, A.B.Hutchinson, S.L.Sansom. Cost effectiveness of the National HIV/AIDS Strategy goal of increasing linkage to care for HIV-infected persons. J Acquir Immune Defic Syndr. 2012;61(1):99–105.
12. R.S.Braithwaite, D.O.Meltzer, J.T.KingJr, D.Leslie, M.S.Roberts. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?Med Care. 2008;46(4):349–356.
13. P.J.Neumann, J.T.Cohen, M.C.Weinstein. Updating cost-effectiveness - the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796–797.
14. A.D.Paltiel, M.C.Weinstein, A.D.Kimmel, G.R.Seage3rd, E.Losina, H.Zhang,. Expanded screening for HIV in the United States - an analysis of cost-effectiveness. N Engl J Med. 2005;352(6):586–595.
15. R.P.Walensky, P.E.Sax, Y.M.Nakamura, M.C.Weinstein, P.P.Pei, K.A.Freedberg, Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med. 2013;158(2):84–92.
16. J.E.Gallant, S.Staszewski, A.L.Pozniak, E.DeJesus, J.M.Suleiman, M.D.Miller, Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292(2):191–201.
17. J.L.Lennox, E.DeJesus, A.Lazzarin, R.B.Pollard, J.V.Madruga, D.S.Berger, Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009;374(9692):796–806.
18. J.M.Molina, P.Cahn, B.Grinsztejn, A.Lazzarin, A.Mills, M.Saag, Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet. 2011;378(9787):238–246.
19. P.E.Sax, E.DeJesus, A.Mills, A.Zolopa, C.Cohen, D.Wohl, Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012;379(9835):2439–2448.
20. K.N.Althoff, S.J.Gange, M.B.Klein, J.T.Brooks, R.S.Hogg, R.J.Bosch, Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis. 2010;50(11):1512–1520.
21. Personal communication with Dr. Keri Althoff on 12 May 2013
22. RED BOOK Online 2014. Micromedex Solutions. Truven Health Analytics Inc. Available from:http://redbook.solutions.aap.org/book.aspx?bookid=1484Accessed September 18, 2015.
23. E.S.Daar, C.Tierney, M.A.Fischl, P.E.Sax, K.Mollan, C.Budhathoki, Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med. 2011;154(7):445–456.
24. M.Johnson, B.Grinsztejn, C.Rodriguez, J.Coco, E.DeJesus, A.Lazzarin, Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS. 2005;19(7):685–694.
25. M.Johnson, B.Grinsztejn, C.Rodriguez, J.Coco, E.DeJesus, A.Lazzarin, 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS. 2006;20(5):711–718.
26. S.A.Riddler, R.Haubrich, A.G.DiRienzo, L.Peeples, W.G.Powderly, K.L.Klingman, Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358(20):2095–2106.
27. The North American AIDS Cohort Collaboration on Research and Design. NA-ACCORD dossier. 2014;. Available from: http://statepiaps.jhsph.edu/naaccord/dossier/NA-ACCORD_Dossier_2014_0404.pdf. Accessed July 24, 2015.
28. A.H.Briggs, K.Claxton, M.Sculpher. Decision Modelling for Health Economic Evaluation. New York: Oxford University Press; 2006.
29. M.G.Hunink, M.C.Weinstein, E.Wittenberg, M.F.Drummond, J.S.Pliskin, J.B.Wong, Heterogeneity and uncertainty. Decision Making in Health and Medicine. 2nd edn. Cambridge, UK: Cambridge University Press; 2014.
30. L.Steuten, G.van de Wetering, K.Groothuis-Oudshoorn, V.Rete. A systematic and critical review of the evolving methods and applications of value of information in academia and practice. Pharmacoeconomics. 2013;31(1):25–48.
31. J.A.Roth, R.Etzioni, T.M.Waters, M.Pettinger, J.E.Rossouw, G.L.Anderson, Economic return from the Women's Health Initiative estrogen plus progestin clinical trial: a modeling study. Ann Intern Med. 2014;160(9):594–602.
32. E.Myers, A.J.McBroom, L.Shen, R.E.Posey, R.Gray, G.D.Sanders. Value-of-Information Analysis for Patient-Centered Outcomes Research Prioritization. Durham, NC: Duke Evidence-based Practice Center; 2012.
33. A.D.Paltiel, S.J.Goldie, E.Losina, M.C.Weinstein, G.R.Seage3rd, A.D.Kimmel. Preevaluation of clinical trial data: the case of preemptive cytomegalovirus therapy in patients with human immunodeficiency virus. Clin Infect Dis. 2001;32(5):783–793.
34. S.B.Lorenzana, M.D.Hughes, B.Grinsztejn, A.C.Collier, P.M.Luz, K.A.Freedberg, Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial. AIDS. 2012;26(9):1083–1093.
35. J.B.Nachega, J.J.Parienti, O.A.Uthman, R.Gross, D.W.Dowdy, P.E.Sax, Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials. Clin Infect Dis. 2014;58(9):1297–1307.
36. H.G.Eichler, S.X.Kong, W.C.Gerth, P.Mavros, B.Jonsson. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?Value Health. 2004;7(5):518–528.
37. U.Siebert, U.Rochau, K.Claxton. When is enough evidence enough? Using systematic decision analysis and value-of-information analysis to determine the need for further evidence. Z Evid Fortbild Qual Gesundhwes. 2013;107(9-10):575–584.
38. A.R.Willan, S.Eckermann. Value of information and pricing new healthcare interventions. Pharmacoeconomics. 2012;30(6):447–459.
39. E.J.Frew, D.K.Whynes, J.L.Wolstenholme. Eliciting willingness to pay: comparing closed-ended with open-ended and payment scale formats. Med Decis Making. 2003;23(2):150–159.
40. S.D.Grosse. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res. 2008;8(2):165–178.
41. R.A.Hirth, M.E.Chernew, E.Miller, A.M.Fendrick, W.G.Weissert. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making. 2000;20(3):332–342.
42. J.T.KingJr, J.Tsevat, J.R.Lave, M.S.Roberts. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation. Med Decis Making. 2005;25(6):667–677.
43. B.Clotet, J.Feinberg, J.van Lunzen, M.A.Khuong-Josses, A.Antinori, I.Dumitru, Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet. 2014;383(9936):2222–2231.
44. M.S.Cohen, Y.Q.Chen, M.McCauley, T.Gamble, M.C.Hosseinipour, N.Kumarasamy, Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.
45. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2008;. Avaliable from: https://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL001226.pdf. Accessed June 16, 2015.
46. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2012;. https://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL003093.pdf. Accessed June 16, 2015.
47. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2014;. https://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL003390.pdf. Accessed June 16, 2015.
48. F.Raffi, A.Rachlis, H.J.Stellbrink, W.D.Hardy, C.Torti, C.Orkin, Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381(9868):735–743.
49. U.S. Food and Drug Administration. FDA approves new drug to treat HIV infection. 2013;. Avaliable from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm364744.htm. Accessed June 16, 2015.
50. U.S. Food and Drug Administration. Approval of new fixed dose combination, TRIUMEQ (abacavir sulfate, dolutegravir, lamivudine). 2014;. Avaliable from: http://content.govdelivery.com/accounts/USFDA/bulletins/cb6dfa/. Accessed June 16, 2015.
51. S.L.Walmsley, A.Antela, N.Clumeck, D.Duiculescu, A.Eberhard, F.Gutierrez, Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807–1818.
52. World Health Organization. Antiretroviral treatment as prevention (TasP) of HIV and TB. 2012;. Avaliable from: http://whqlibdoc.who.int/hq/2012/WHO_HIV_12_eng.pdf?ua = 1. Accessed June 8, 2015.
53. P.E.Sax, C.Tierney, A.C.Collier, M.A.Fischl, K.Mollan, L.Peeples, Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med. 2009;361(23):2230–2240.
54. S.J.Goldie, Y.Yazdanpanah, E.Losina, M.C.Weinstein, X.Anglaret, R.P.Walensky, Cost-effectiveness of HIV treatment in resource-poor settings - the case of Côte d'Ivoire. N Engl J Med. 2006;355(11):1141–1153.